PL2970377T3 - Sposób wytwarzania preparatu igg pochodzących z surowicy, wzbogaconego w naturalne igg związane z chorobą mózgu - Google Patents

Sposób wytwarzania preparatu igg pochodzących z surowicy, wzbogaconego w naturalne igg związane z chorobą mózgu

Info

Publication number
PL2970377T3
PL2970377T3 PL14721128T PL14721128T PL2970377T3 PL 2970377 T3 PL2970377 T3 PL 2970377T3 PL 14721128 T PL14721128 T PL 14721128T PL 14721128 T PL14721128 T PL 14721128T PL 2970377 T3 PL2970377 T3 PL 2970377T3
Authority
PL
Poland
Prior art keywords
enriched
manufacturing
igg
brain disease
natural
Prior art date
Application number
PL14721128T
Other languages
English (en)
Inventor
Lucia Gnauer
Harald Arno Butterweck
Theresa BAUER
Alfred Weber
Wolfgang Teschner
Hans-Peter Schwarz
Original Assignee
Baxalta Incorporated
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Incorporated, Baxalta GmbH filed Critical Baxalta Incorporated
Publication of PL2970377T3 publication Critical patent/PL2970377T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/027—Nanofiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2623—Ion-Exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL14721128T 2013-03-15 2014-03-14 Sposób wytwarzania preparatu igg pochodzących z surowicy, wzbogaconego w naturalne igg związane z chorobą mózgu PL2970377T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794378P 2013-03-15 2013-03-15
PCT/US2014/028953 WO2014144511A1 (en) 2013-03-15 2014-03-14 Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP14721128.8A EP2970377B1 (en) 2013-03-15 2014-03-14 Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs

Publications (1)

Publication Number Publication Date
PL2970377T3 true PL2970377T3 (pl) 2020-04-30

Family

ID=50631072

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14721128T PL2970377T3 (pl) 2013-03-15 2014-03-14 Sposób wytwarzania preparatu igg pochodzących z surowicy, wzbogaconego w naturalne igg związane z chorobą mózgu

Country Status (12)

Country Link
US (5) US9896501B2 (pl)
EP (2) EP3623377A1 (pl)
AU (1) AU2013203043B2 (pl)
DK (1) DK2970377T3 (pl)
ES (1) ES2763396T3 (pl)
HR (1) HRP20200035T1 (pl)
HU (1) HUE047475T2 (pl)
LT (1) LT2970377T (pl)
PL (1) PL2970377T3 (pl)
PT (1) PT2970377T (pl)
SI (1) SI2970377T1 (pl)
WO (1) WO2014144511A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
WO2015137531A1 (ko) * 2014-03-11 2015-09-17 주식회사 녹십자홀딩스 면역글로불린의 정제방법
CA2941230C (en) * 2014-03-11 2020-08-25 Green Cross Holdings Corporation Method for purifying immunoglobulin
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
SG11201901273TA (en) * 2016-08-18 2019-03-28 Alkahest Inc Blood plasma fractions as a treatment for aging-associated cognitive disorders
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
US20210154883A1 (en) * 2018-04-13 2021-05-27 Tricoya Technologies Ltd Acetylated Wood and Method of Making Same
RU2694620C1 (ru) * 2018-10-17 2019-07-16 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения и очистки иммуноглобулинов
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
BR112022000249A2 (pt) 2019-07-30 2022-05-17 Kindred Biosciences Inc Anticorpos de parvovírus para uso veterinário
WO2021202373A1 (en) * 2020-03-31 2021-10-07 Baxalta Incorporated A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
AU2021303496A1 (en) * 2020-07-10 2023-02-02 Grifols Worldwide Operations Limited Method for obtaining a composition comprising human plasma-derived immunoglobulin M
CN114736294B (zh) * 2022-04-24 2024-08-13 华兰生物工程重庆有限公司 一种破伤风免疫球蛋白的纯化方法及其亲和层析填料
EP4518875A1 (en) * 2022-05-02 2025-03-12 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296027A (en) * 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4434093A (en) * 1982-07-26 1984-02-28 Ortho Diagnostic Systems Inc. Methods for preparation of HBs Ag free gamma globulins
US5258503A (en) * 1987-09-08 1993-11-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Autoantibody adsorbent and apparatus for removing autoantibodies using the same
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
DK0659767T4 (da) * 1993-12-27 2003-02-10 Zlb Bioplasma Ag Fremgangsmåde til fremstilling af et koncentrat af anti-D-immunoglobulin G og et farmaceutisk præparat, som indeholder dette
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
AT404358B (de) * 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
ES2421736T3 (es) * 1998-06-09 2013-09-05 Csl Behring Ag Procedimiento para la preparación de inmunoglobulinas para administración intravenosa y otros productos inmunoglobulínicos
KR100501263B1 (ko) * 1998-06-09 2005-07-18 스태튼스 세룸 인스티튜트 정맥 주사용 면역글로불린의 제조 방법 및 그 외의 면역글로불린 제품
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
CA2496060C (en) * 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
US20050221414A1 (en) 2004-03-31 2005-10-06 Katalin Varadi Kit for measuring the thrombin generation in a sample of a patient's blood or plasma
US20060099211A1 (en) * 2004-04-12 2006-05-11 Carmen Monthe Safer, more potent human immunoglobulin preparations for treating Alzheimer's disease
US7993580B2 (en) * 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
US8354249B2 (en) * 2005-08-11 2013-01-15 Omrix Biopharmaceuticals Ltd. Intravenous immunoglobulin composition
DK2104682T3 (en) 2007-01-11 2017-01-16 Michael Bacher DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES
CA2673771A1 (en) 2007-01-17 2008-07-24 Merck Serono S.A. Process for the purification of fc-containing proteins
WO2009005870A2 (en) * 2007-04-12 2009-01-08 Omrix Biopharmaceuticals Ltd, Products for prophylaxis and/or treatment of viral diseases and method of making and using same
WO2009043103A1 (en) * 2007-10-02 2009-04-09 Csl Limited Therapeutic antibody purification method and method of use
ES2587742T3 (es) * 2007-12-27 2016-10-26 Baxalta GmbH Métodos para diferenciar en una muestra proteína derivada de plasma de proteína recombinante
PT2271382E (pt) 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
US20100040601A1 (en) * 2008-06-10 2010-02-18 Cantin Edouard M Compositions and methods for treating herpes simplex virus infections and related diseases
FR2939667B1 (fr) * 2008-12-17 2012-01-27 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo
KR101464032B1 (ko) * 2009-05-27 2014-11-27 백스터 인터내셔널 인코포레이티드 피하 사용을 위한 고 농축 면역글로불린 제제의 제조 방법
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
KR20130128382A (ko) * 2010-10-13 2013-11-26 옥타파마 아게 보체 인자 ｈ의 정제 방법
US20120183527A1 (en) * 2011-01-18 2012-07-19 Baxter International Inc. Measurement of anti-amyloid antibodies in human blood
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
CA2843197A1 (en) 2011-07-29 2013-02-07 Eleven Biotherapeutics, Inc. Purified proteins
EA030251B1 (ru) * 2011-08-26 2018-07-31 Баксалта Инкорпорейтид Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин
PL2791675T3 (pl) 2011-12-13 2018-10-31 Baxalta GmbH Pomiar autoprzeciwciał w warunkach niskiej przewodności
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs

Also Published As

Publication number Publication date
EP2970377A1 (en) 2016-01-20
US20140271669A1 (en) 2014-09-18
SI2970377T1 (sl) 2020-04-30
EP3623377A1 (en) 2020-03-18
AU2013203043A1 (en) 2014-10-02
US9556261B2 (en) 2017-01-31
US20260049127A1 (en) 2026-02-19
US20140271679A1 (en) 2014-09-18
US9896501B2 (en) 2018-02-20
US20170218051A1 (en) 2017-08-03
US10738107B2 (en) 2020-08-11
US12365723B2 (en) 2025-07-22
LT2970377T (lt) 2020-02-10
HUE047475T2 (hu) 2020-04-28
DK2970377T3 (da) 2020-01-27
ES2763396T3 (es) 2020-05-28
HRP20200035T1 (hr) 2020-10-30
AU2013203043B2 (en) 2016-10-06
PT2970377T (pt) 2020-01-21
WO2014144511A1 (en) 2014-09-18
EP2970377B1 (en) 2019-12-04
US20210054058A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
PL2970377T3 (pl) Sposób wytwarzania preparatu igg pochodzących z surowicy, wzbogaconego w naturalne igg związane z chorobą mózgu
IL290613A (en) Humanized or chimeric cd3 antibodies
IL291446A (en) Anti-trop2 antibodies and methods for producing same
IL233539B (en) Model-based reconstruction of the heart from sparse samples
HUE051982T2 (hu) Anti-alfa-szinuklein antitestek és alkalmazási eljárások
DK3015467T3 (da) Morpholino-oligonukleotidfremstillingsfremgangsmåde
ZA201504952B (en) Human antibodies to respiratory syncytial virus f protein and methods
IL240511A0 (en) Human antibodies to nav1.7
HUE050159T2 (hu) Anti-CD3 antitestek és alkalmazási eljárások
SMT202000512T1 (it) Anticorpi anti-tau umani
DK2953976T3 (da) Specifikke modificeringssteder i antistoffer til fremstilling af immunkonjugater
PL3010910T3 (pl) Związki pirymidynodionu przeciwko chorobom serca
HUE049171T2 (hu) Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek
HUE043875T2 (hu) Humanizált, kallikrein-2 elleni antitest
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
CL2015002750A1 (es) Anticuerpos humanos pac1
HRP20190210T1 (hr) Enterički premazani multipartikulatni pripravak s proteinskim podslojem
PL3005298T3 (pl) Sposób rekonstruowania obiektu na podstawie rzutowanych widoków
PL3091003T3 (pl) Pochodna 1,2‑naftochinonu i sposób jej przygotowania
IL240753B (en) Methods for purifying antibodies
ES2777200T8 (es) Procedimiento para la preparación de 3-aminopiperidina enriquecida enantioméricamente
PL3172969T3 (pl) Sposób wytwarzania kompozycji beta-kazeiny
IL238545B (en) Plants for production of therapeutic proteins
EP3043640A4 (en) MECHANICAL BIOLOGICAL FILTER
IL246409A0 (en) Ex vivo antibody production